At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
QNRX Quoin Pharmaceuticals
Closed 10-23 16:00:00 EDT
4.02
+0.01
+0.25%
盘后3.95
-0.07-1.74%
18:37 EDT
High4.08Low4.02Vol2.16K
Open4.08D1 Closing4.01Amplitude1.53%
Mkt Cap19.31MTradable Cap18.60MTotal Shares4.80M
T/O8.85KT/O Rate0.05%Tradable Shares4.63M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Quoin Reports Qrx003 Clears Skin in Pediatric Netherton Syndrome Case Study
Reuters  ·  10-20
Quoin Reports Qrx003 Clears Skin in Pediatric Netherton Syndrome Case Study
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
GlobeNewswire  ·  10-20
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
Quoin Pharmaceuticals Initiated at Buy by Canaccord Genuity
Dow Jones  ·  10-19
Quoin Pharmaceuticals Initiated at Buy by Canaccord Genuity
Canaccord Genuity Initiates Quoin Pharmaceuticals at Buy With $18 Price Target
MT Newswires Live  ·  10-19
Canaccord Genuity Initiates Quoin Pharmaceuticals at Buy With $18 Price Target
Quoin’s QRX003 granted Orphan Drug Designation in Europe
TIPRANKS  ·  10-14
Quoin’s QRX003 granted Orphan Drug Designation in Europe
Quoin Says EMA Grants Orphan Drug Designation for Qrx003 in Peeling Skin Syndrome
Reuters  ·  10-14
Quoin Says EMA Grants Orphan Drug Designation for Qrx003 in Peeling Skin Syndrome
BTIG Initiates Quoin Pharmaceuticals at Buy With $14 Price Target
MT Newswires Live  ·  10-12
BTIG Initiates Quoin Pharmaceuticals at Buy With $14 Price Target
Quoin Pharmaceuticals Ltd : Btig Initiates Coverage with Buy Rating; Target Price $14
THOMSON REUTERS  ·  10-12
Quoin Pharmaceuticals Ltd : Btig Initiates Coverage with Buy Rating; Target Price $14
Quoin Pharmaceuticals Price Target Announced at $14.00/Share by BTIG
Dow Jones  ·  10-12
Quoin Pharmaceuticals Price Target Announced at $14.00/Share by BTIG
Quoin Says Qrx003 Pediatric Compassionate-Use Case Report Accepted for Publication in Dermatology and Therapy
Reuters  ·  10-06
Quoin Says Qrx003 Pediatric Compassionate-Use Case Report Accepted for Publication in Dermatology and Therapy
Quoin Pharmaceuticals Price Target Announced at $20.00/Share by Lake Street
Dow Jones  ·  09-23
Quoin Pharmaceuticals Price Target Announced at $20.00/Share by Lake Street
Quoin Pharma Wins FDA Fast Track Status for Qrx003 in Peeling Skin Syndrome
Reuters  ·  09-22
Quoin Pharma Wins FDA Fast Track Status for Qrx003 in Peeling Skin Syndrome
Quoin Pharmaceuticals registers to sell 9.37M ADRs for holders
TIPRANKS  ·  09-19
Quoin Pharmaceuticals registers to sell 9.37M ADRs for holders
Quoin Pharmaceuticals Gains FDA Rare Pediatric Designation
TIPRANKS  ·  09-11
Quoin Pharmaceuticals Gains FDA Rare Pediatric Designation
Quoin Evaluates Qrx003 in Phase 2/3 Trial for Netherton Syndrome
Reuters  ·  09-10
Quoin Evaluates Qrx003 in Phase 2/3 Trial for Netherton Syndrome
Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU
GlobeNewswire  ·  09-10
Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU
Quoin Pharmaceuticals granted Rare Pediatric Disease Designation for QRX003
TIPRANKS  ·  09-08
Quoin Pharmaceuticals granted Rare Pediatric Disease Designation for QRX003
Quoin Says FDA Grants Rare Pediatric Disease Designation for Qrx003 in Peeling Skin Syndrome
Reuters  ·  09-08
Quoin Says FDA Grants Rare Pediatric Disease Designation for Qrx003 in Peeling Skin Syndrome
Analysts’ Top Healthcare Picks: Dogwood Therapeutics (DWTX), Quoin Pharmaceuticals (QNRX)
TIPRANKS  ·  09-04
Analysts’ Top Healthcare Picks: Dogwood Therapeutics (DWTX), Quoin Pharmaceuticals (QNRX)
Quoin Pharmaceuticals Director Anthony James Culverwell Acquires Shares Worth $29,988.48
Reuters  ·  09-02
Quoin Pharmaceuticals Director Anthony James Culverwell Acquires Shares Worth $29,988.48

Introduction

Company Name.
Quoin Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.
Issue price:
--